ONCAlert | Upfront Therapy for mRCC
Videos  >  

Gilteritinib Relapse Leads to Loss of FLT3-TKD Mutation in Patient With AML

Adam Fisch, MD, PhD
Published Online:7:53 PM, Fri January 10, 2020

Adam Fisch, MD, PhD, a clinical fellow in molecular genetic pathology at the Brigham’s Women’s Hospital, discusses the key points from a patient case he presented at the 2019 Association for Molecular Pathology (AMP) Annual Meeting and Expo (AMP 2019), in which the patient with acute myeloid leukemia (AML) harboring a FLT3-TKD mutation lost the mutation following relapse on gilteritinib (Xospata).

The FLT3 tyrosine kinase inhibitor gilteritinib, which was approved by the FDA in November of 2018 for adult patients with FLT3-mutant AML, is efficacious in many different patients with FLT3-mutant AML, but the case of the patient losing the mutation upon relapse is unexpected. This kind of event has not been reported much in literature, and there is not a lot of discussion about the disappearance of a FLT3-TKD following relapse on a TKI, Fisch says.

This case provides insight into the possible subclonal dynamics of the disease. Fisch says he wants other researchers to know that this happened and is something worth investigating further in the future. He also emphasizes to clinicians that should they see this type of pattern in their patients, it is something that has occurred before. This case may be something clinicians will see down the road with gilteritinib treatment, he concludes.
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.